5 Tiny Cryptos That Could Soar During 2024 Crypto Bull Run One of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.

Get His #1 Coin For 2024 FREE By Clicking Here

Brady Johnson Biography and Net Worth

VP of Cidara Therapeutics

Brady Johnson occupies the position of Chief Accounting Officer & VP-Finance at Cidara Therapeutics, Inc.

How do I contact Brady Johnson?: The corporate mailing address for Mr. Johnson and other Cidara Therapeutics executives is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. Cidara Therapeutics can also be reached via phone at (858) 752-6170 and via email at [email protected]. Learn More on Brady Johnson's contact information.
Has Brady Johnson been buying or selling shares of Cidara Therapeutics?: Brady Johnson has not been actively trading shares of Cidara Therapeutics during the last quarter. Most recently, Brady Johnson sold 654 shares of the business's stock in a transaction on Monday, March 21st. The shares were sold at an average price of $0.81, for a transaction totalling $529.74. Learn More on Brady Johnson's trading history.
Who are Cidara Therapeutics' active insiders?: Cidara Therapeutics' insider roster includes Neil Abdollahian (Insider), Paul Daruwala (COO), Timothy Franson (Director), Brady Johnson (VP), Jessica Oien (General Counsel), Preetam Shah (CFO), Jeffrey Stein (CEO), and Leslie Tari (Insider). Learn More on Cidara Therapeutics' active insiders.
Are insiders buying or selling shares of Cidara Therapeutics?: In the last twelve months, Cidara Therapeutics insiders bought shares 2 times. They purchased a total of 60,000 shares worth more than $57,700.00. In the last twelve months, insiders at the biotechnology company sold shares 4 times. They sold a total of 78,902 shares worth more than $58,035.66. The most recent insider tranaction occured on March, 11th when insider Leslie Tari sold 21,029 shares worth more than $14,089.43. Insiders at Cidara Therapeutics own 7.4% of the company. Learn More about insider trades at Cidara Therapeutics.
Information on this page was last updated on 3/11/2024.

Brady Johnson Insider Trading History at Cidara Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
3/21/2022	Sell	654	$0.81	$529.74
3/11/2022	Sell	945	$0.71	$670.95
1/5/2022	Sell	416	$1.25	$520.00

Brady Johnson Buying and Selling Activity at Cidara Therapeutics

Cidara Therapeutics Company Overview

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Today's Range

Now: $0.68

$0.68

$0.74

50 Day Range

MA: $0.78

$0.64

$1.16

2 Week Range

Now: $0.68

$0.59

$1.48

Volume

352,272 shs

Average Volume

653,739 shs

Market Capitalization

$61.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98

The #1 Crypto for 2024

From InvestorPlace | Ad